Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
TRVI Trevi Therapeutics
1.730
-0.020-1.14%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
-14.69% 7.82M -13.15% 7.03M -0.04% 32.48M -10.01% 8.27M
Selling and administrative expenses
1.8% 2.72M -4.8% 2.38M -6.58% 9.49M -20.47% 2.09M
-General and administrative expense
1.8% 2.72M -4.8% 2.38M -6.58% 9.49M -20.47% 2.09M
Research and development costs
-21.47% 5.1M -16.89% 4.65M 2.94% 22.98M -5.81% 6.18M
Operating profit
14.69% -7.82M 13.15% -7.03M 0.04% -32.48M 10.01% -8.27M
Net non-operating interest income expense
65.99% -100K -2.41% -298K -328.78% -1.19M -306K
Non-operating interest income
9650% 195K 33.33% 4K -94.38% 10K -- 3K
Non-operating interest expense
-35.47% 191K -37.07% 185K 163.6% 1.2M -- 664K
Total other finance cost
-- 104K -- 117K -- -- -- --
Other net income (expense)
59.4% -136K -83.33% -11K -3155.56% -293K 116.93% 53K
Gain on sale of security
-440% -136K -83.33% -11K 1011.11% 82K -- 53K
Other non- operating income (expenses)
-- -- -- -- -- -375K -- 0
Income before tax
17.76% -8.06M 12.54% -7.33M -3.62% -33.96M 10.31% -8.53M
Income tax
-100% -4K 66.67% -5K -16.67% -21K -135.29% -6K
Net income
17.79% -8.05M 12.45% -7.33M -3.61% -33.94M 10.53% -8.52M
Net income continuous Operations
17.79% -8.05M 12.45% -7.33M -3.61% -33.94M 10.53% -8.52M
Minority interest income
Net income attributable to the parent company
17.79% -8.05M 12.45% -7.33M -3.61% -33.94M 10.53% -8.52M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
17.79% -8.05M 12.45% -7.33M -3.61% -33.94M 10.53% -8.52M
Basic earnings per share
71.43% -0.14 44.19% -0.24 17.68% -1.49 53.26% -0.24
Diluted earnings per share
71.43% -0.14 44.19% -0.24 17.68% -1.49 53.26% -0.24
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion with Explanation--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
CEO: Good, Jennifer L.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top